Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | GIPR | P48546 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | EIF4EBP1 | Q13541 | 3/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | MARS1 | P56192 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601481 | 0.92 | CYP11B1 (0.42) | MKNK1MKNK2 | |
| SCHEMBL6606254 | 0.86 | TP53 (0.47) | TP53MDM2EIF4EBP1 | |
| SCHEMBL6606542 | 0.86 | TP53 (0.47) | TP53MDM2PDE4BGCGRGIPR | |
| SCHEMBL6803407 | 0.86 | TP53 (0.44) | TP53MDM2GCGRGIPRKMO | |
| SCHEMBL6804559 | 0.85 | TP53 (0.43) | TP53MDM2PDE4BGCGRGIPR | |
| SCHEMBL6606062 | 0.85 | TP53 (0.46) | TP53MDM2GCGRGIPR | |
| SCHEMBL6803960 | 0.84 | TP53 (0.43) | TP53MDM2PDE4BGCGRGIPR | |
| SCHEMBL6809196 | 0.84 | TP53 (0.46) | TP53MDM2PDE4BGCGRGIPR | |
| SCHEMBL6603996 | 0.84 | TP53 (0.44) | TP53MDM2GCGRGIPRKMO | |
| SCHEMBL6602139 | 0.84 | TP53 (0.47) | TP53MDM2GCGRGIPRKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | MKI67, CDK4, FLT4 | TP53 35/4885MDM2 1509/4885MKNK1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.